Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.

scientific article

Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/JNCI/DJW290
P698PubMed publication ID28130475

P50authorYiwey ShiehQ81345889
Laura EssermanQ91960202
P2093author name stringElad Ziv
Jeffrey A Tice
Lisa Madlensky
Laura J Van't Veer
Martin Eklund
Allison Stover Fiscalini
Carlie K Thompson
Sarah D Sawyer
Athena Breast Health Network Investigators
P2860cites workAverage risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studiesQ24531993
Screening for breast cancer: an update for the U.S. Preventive Services Task ForceQ24615837
Gene-environment interaction and risk of breast cancerQ26772236
Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer SocietyQ27347760
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutationsQ28215462
American Cancer Society guidelines for breast screening with MRI as an adjunct to mammographyQ28295438
Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing riskQ28390064
Presymptomatic risk assessment for chronic non-communicable diseasesQ28743818
Large-scale genotyping identifies 41 new loci associated with breast cancer riskQ29416989
Population-based screening for cancer: hope and hype.Q30251601
A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.Q37284382
Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening StrategiesQ37364628
Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk modelQ37378034
ACR Appropriateness Criteria: follow-up of Hodgkin's lymphomaQ37764404
A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performanceQ37950847
Benefits and Harms of Breast Cancer Screening: A Systematic ReviewQ38616415
Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force RecommendationQ38693248
Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventive Services Task Force RecommendationQ38693328
CDH1 germline mutations and hereditary lobular breast cancer.Q38694163
Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC CarriersQ39437211
Mammography Use and Physician Recommendation After the 2009 U.S. Preventive Services Task Force Breast Cancer Screening RecommendationsQ40176894
Breast cancer risk prediction using a clinical risk model and polygenic risk scoreQ40605693
Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening programQ44609406
Risk factors for breast cancer according to estrogen and progesterone receptor statusQ44753983
Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphomaQ45854491
Personalized Screening for Breast Cancer: A Wolf in Sheep's Clothing?Q46114265
Predicting risk of breast cancer in postmenopausal women by hormone receptor statusQ46901894
Validation studies for models projecting the risk of invasive and total breast cancer incidence.Q50651945
Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.Q50748795
Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density.Q51933968
A breast cancer prediction model incorporating familial and personal risk factors.Q52000310
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.Q52274948
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation StatementQ54092157
ACR Appropriateness Criteria Breast Cancer ScreeningQ57132506
Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study.Q30620197
Validation of the Gail et al. model of breast cancer risk prediction and implications for chemopreventionQ32133889
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predispositionQ33205307
Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancerQ33549627
TP53 mutations in human cancers: origins, consequences, and clinical useQ33685392
Breast cancer after chest radiation therapy for childhood cancerQ33910979
Counselling framework for moderate-penetrance cancer-susceptibility mutationsQ33911135
Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasiaQ34049245
A comprehensive examination of breast cancer risk loci in African American womenQ34211808
Assessment of clinical validity of a breast cancer risk model combining genetic and clinical informationQ34267477
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.Q34314370
Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task ForceQ34339445
Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25.Q34375940
Cancer risks and mortality in heterozygous ATM mutation carriersQ34422846
Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation StatementQ34508652
Frequency and spectrum of cancers in the Peutz-Jeghers syndromeQ34567595
Polygenic susceptibility to prostate and breast cancer: implications for personalised screeningQ34977428
Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortiumQ35166701
Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programmeQ35441054
Lifetime cancer risks in individuals with germline PTEN mutations.Q35681689
Diversity in Clinical and Biomedical Research: A Promise Yet to Be FulfilledQ35869663
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancerQ35996692
Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast CancerQ36090967
The contributions of breast density and common genetic variation to breast cancer riskQ36137764
Gene-panel sequencing and the prediction of breast-cancer riskQ36175072
Provider Attitudes and Screening Practices Following Changes in Breast and Cervical Cancer Screening GuidelinesQ36426749
Prediction of breast cancer risk based on profiling with common genetic variantsQ36583004
Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family RegistryQ36619329
Genetic susceptibility to triple-negative breast cancerQ36846498
Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controlsQ36856357
Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapyQ36976948
Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectivenessQ37139381
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive modelQ37172219
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectbreast cancer screeningQ17011492
P577publication date2017-01-27
P1433published inJournal of the National Cancer InstituteQ400279
P1476titleBreast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial
P478volume109

Reverse relations

cites work (P2860)
Q6411528410-year performance of four models of breast cancer risk: a validation study
Q92654615Age-based versus Risk-based Mammography Screening in Women 40-49 Years Old: A Cross-sectional Study
Q88660564Breast Cancer Screening in Primary Care: A Call for Development and Validation of Patient-Oriented Shared Decision-Making Tools
Q61443339Cancer prevention and screening: the next step in the era of precision medicine
Q89746441Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field
Q47703662Common Genetic Variation and Breast Cancer Risk - Past, present, and future
Q90213124Community education to enhance the more equitable use of precision medicine in Northern Manhattan
Q92528444Comparative Validation of Breast Cancer Risk Prediction Models and Projections for Future Risk Stratification
Q47298550Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants
Q38371172E-Science technologies in a workflow for personalized medicine using cancer screening as a case study
Q89799256Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder Perspectives
Q64080586Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer
Q90690238Interval breast cancer risk associations with breast density, family history and breast tissue aging
Q64123868Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families
Q39270600Managing hereditary breast cancer risk in women with and without ovarian cancer
Q47932976Optical assessment of mammographic breast density by a 12-wavelength vs a continuous-spectrum optical spectroscopy device
Q103027570Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction
Q93060888Paradigm Shift From Halstedian Radical Mastectomy to Personalized Medicine
Q57453316Personalised medicine and population health: breast and ovarian cancer
Q54965951Personalized cancer screening: helping primary care rise to the challenge.
Q96577047Personalized early detection and prevention of breast cancer: ENVISION consensus statement
Q62583133Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
Q55010484Precision Medicine for Breast Cancer: The Paths to Truly Individualized Diagnosis and Treatment.
Q52648008Precision medicine screening using whole-genome sequencing and advanced imaging to identify disease risk in adults.
Q91458164Precision risk-based screening might maximize benefit and minimize harm
Q92152748Response to Peshkin, Isaacs, and Schwartz
Q54950358Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data.
Q47130981The Complexity of Achieving the Promise of Precision Breast Cancer Screening.
Q92282029The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches
Q41701590The WISDOM Study: breaking the deadlock in the breast cancer screening debate
Q64240122Towards a more precise and individualized assessment of breast cancer risk
Q59335358Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer
Q90665404We need more evidence to answer questions about screening
Q60927268What do European women know about their female cancer risks and cancer screening? A cross-sectional online intervention survey in five European countries

Search more.